ERBB2 and ductal breast carcinoma in situ: Fifteen to 20% of breast cancer patients have a human epidermal growth factor-2 (HER2)-positive tumor - and HER2 is expressed at even higher levels (up to 50%) in patients with ductal carcinoma in situ [4, 5].